EFFICACY AND SAFETY OF DASATINIB VS. IMATINIB IN LATIN AMERICAN SUBPOPULATION FROM THE DASISION TRIAL IN PATIENTS WITH NEWLY DIAGNOSED CHRONIC MYELOID LEUKEMIA (CML) IN CHRONIC PHASE (CP)

被引：0
|
作者：
Enrico, A. [1 ]
Milone, J. [1 ]
Moiraghi, B. [2 ]
Casanova, L. [3 ,4 ]
Undurraga, M. S. [5 ]
Olivera, L. Enciso [6 ,7 ]
Bullorsky, E. [8 ]
Navarro Cabrera, J. [9 ]
Pagnano, K. [10 ]
De Riz, M. [11 ]
Pavlovsky, C. [12 ]
机构：
[1] Hosp Italiano La Plata, La Plata, Buenos Aires, Argentina
[2] Hosp JM Ramos Mejia, Caba, Argentina
[3] Inst Nacl Enfermedades Neoplas, Dept Med Oncol, Lima, Peru
[4] Clin Oncol Miraflores, Dept Med Oncol, Lima, Peru
[5] Hosp Salvador, Santiago, Chile
[6] Inst Nacl Cancerol Bogota, Bogota, Colombia
[7] Univ Nacl Colombia, Bogota, Colombia
[8] Hosp Britanico Buenos Aires, Caba, Argentina
[9] Hosp Nacl Edgardo Rebagliati Martins, Lima, Peru
[10] Univ Estadual Campinas, Hemoctr Unicamp, Campinas, SP, Brazil
[11] Bristol Myers Squibb, Dept Med, Buenos Aires, DF, Argentina
[12] FUNDALEU, Caba, Argentina
来源：
HAEMATOLOGICA | 2015年 / 100卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
E1119
引用
收藏
页码：446 / 447
页数：2
相关论文
共 50 条
  • [21] EPIC: A PHASE 3 TRIAL OF PONATINIB VS IMATINIB IN PATIENTS (PTS) WITH NEWLY DIAGNOSED CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CP-CML)
    Chuah, C.
    Guerci-Bresler, A.
    Rosti, G.
    Simpson, D.
    Lustgarten, S.
    Trede, N.
    Rivera, V. M.
    Clackson, T.
    Haluska, F. G.
    Baccarani, M.
    Cortes, J. E.
    Guilhot, F.
    Hochhaus, A.
    Hughes, T.
    Kantarjian, H.
    Shah, N. P.
    Talpaz, M.
    Deininger, M. W.
    Lipton, J. H.
    HAEMATOLOGICA, 2014, 99 : 238 - 238
  • [22] Preliminary comparison of efficacy and safety of dasatinib and imatinib in newly diagnosed chronic myeloid leukemia
    周励
    ChinaMedicalAbstracts(InternalMedicine), 2013, 30 (02) : 123 - 123
  • [23] Epic: A Phase 3 Trial of Ponatinib Compared with Imatinib in Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CP-CML)
    Lipton, Jeffrey H.
    Chuah, Charles
    Guerci-Bresler, Agnes
    Rosti, Gianantonio
    Simpson, David
    Assouline, Sarit
    Etienne, Gabriel
    Nicolini, Franck E.
    Le Coutre, Philipp
    Clark, Richard
    Stenke, Leif
    Andorsky, David
    Oehler, Vivian
    Lustgarten, Stephanie
    Rivera, Victor M.
    Clackson, Tim
    Haluska, Frank G.
    Baccarani, Michele
    Cortes, Jorge E.
    Guilhot, Francois
    Hochhaus, Andreas
    Hughes, Timothy P.
    Kantarjian, Hagop M.
    Shah, Neil P.
    Talpaz, Moshe
    Deininger, Michael W.
    BLOOD, 2014, 124 (21)
  • [24] Impact of dose reductions on 5-year efficacy in newly diagnosed patients with chronic myeloid leukemia in chronic phase (CML-CP) from DASISION.
    Cortes, Jorge E.
    Hochhaus, Andreas
    Kantarjian, Hagop M.
    Guilhot, Francois
    Kota, Vamsi K.
    Hughes, Timothy P.
    Shelat, Suresh
    Li, Li
    Jabbour, Elias
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [25] COMPARATIVE EFFICACY OF IMATINIB, DASATINIB AND NILOTINIB FOR NEWLY DIAGNOSED CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CML-CP): A META-ANALYSIS AND INDIRECT COMPARISON
    Park, J.
    Kwon, H.
    Shin, M.
    Shin, S.
    Lee, J. Y.
    VALUE IN HEALTH, 2015, 18 (07) : A433 - A433
  • [26] Relationship Between High Body Mass Index (BMI) and Treatment Outcomes in Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Treated with Dasatinib or Imatinib: Retrospective Analysis of the Phase 3 DASISION Trial
    Breccia, Massimo
    Cortes, Jorge E.
    Shah, Neil P.
    Saglio, Giuseppe
    Jimenez-Velasco, Antonio
    Le Coutre, Philipp
    Brun, Alexander
    DeGutis, Irene
    Bathena, Sai
    Sy, Oumar
    Jabbour, Elias
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 : S230 - S230
  • [27] THE IMPACT OF EARLY MOLECULAR RESPONSE ON LONG-TERM OUTCOMES IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CML-CP) TREATED WITH DASATINIB OR IMATINIB FROM THE DASISION TRIAL
    Stegelmann, F.
    Shah, N. P.
    Saglio, G.
    Hochhaus, A.
    Bilmes, R.
    Li, L.
    Cortes, J. E.
    HAEMATOLOGICA, 2016, 101 : 240 - 240
  • [28] Efficacy and safety of bosutinib versus imatinib for newly diagnosed chronic myeloid leukemia in the Asian subpopulation of the phase 3 BFORE trial
    Charles Chuah
    Liang Piu Koh
    Tontanai Numbenjapon
    Dae Young Zang
    Kiat Hoe Ong
    Young Rok Do
    Masayuki Ohkura
    Chiho Ono
    Andrea Viqueira
    Jorge E. Cortes
    Tim H. Brümmendorf
    International Journal of Hematology, 2021, 114 : 65 - 78
  • [29] Efficacy and safety of bosutinib versus imatinib for newly diagnosed chronic myeloid leukemia in the Asian subpopulation of the phase 3 BFORE trial
    Chuah, Charles
    Koh, Liang Piu
    Numbenjapon, Tontanai
    Zang, Dae Young
    Ong, Kiat Hoe
    Do, Young Rok
    Ohkura, Masayuki
    Ono, Chiho
    Viqueira, Andrea
    Cortes, Jorge E.
    Brummendorf, Tim H.
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2021, 114 (01) : 65 - 78
  • [30] Clinical Efficacy and Safety Of Dasatinib For Newly Diagnosed Chronic Myeloid Leukemia In Chronic Phase In Japan
    Yamaguchi, Kohei
    Murai, Kazunori
    Ito, Shigeki
    Akagi, Tomoaki
    Ogawa, Kazuei
    Meguro, Kuniaki
    Inomata, Mitsue
    Watanabe, Reiko
    Miyagishima, Takuto
    Wakasa, Kentaro
    Shindo, Motohiro
    Tsukushi, Yasuhiko
    Kubo, Kohmei
    Ishida, Yoji
    BLOOD, 2013, 122 (21)
12345